ArticleApplied biochemistry and biotechnology2025
Inhibitory Effects of Hesperetin and EGCG in the Lung Cancer Progression involves impairment in TOP2A gene expression regulation.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lung cancer (LC) remains the leading cause of death among all cancer-related mortalities. Despite advances in Non-Small Cell Lung Cancer (NSCLC) treatment, rising drug resistance necessitates the development of new therapeutics targeting relevant biomarkers. Understanding resistance mechanisms is key to improving treatment effectiveness and overcoming drug resistance. This study aims to identify crucial biomarkers and evaluate potential drug-like compounds targeting them using both in silico and in vitro analyses. Ten key biomarkers associated with LC-including Assembly Factor for Spindle Microtubules (ASPM), Budding Uninhibited by Benzimidazoles 1 (BUB1), Centromere Protein F (CENPF), DNA Topoisomerase II Alpha (TOP2A), TPX2 Microtubule Nucleation Factor (TPX2), Kinesin Family Member 15 (KIF15), Ubiquitin Conjugating Enzyme E2 C (UBE2C), Marker of Proliferation Ki-67 (MK167), Hyaluronan-Mediated Motility Receptor (HMMR), and Cyclin B2 (CCNB2)-were identified from GEO datasets (GSE4882, GSE40275, GSE22874, GSE166720, GSE7880, GSE1987, GSE45142, GSE162102, GSE63571, and GSE23361) using the GEO2R tool. A molecular docking study involving 18 natural compounds was performed against these top 10 biomarker proteins. The compounds hesperetin (binding affinity [BA] = -10.5 kcal/mol; root mean square deviation [RMSD] = 1.569 Å) and epigallocatechin gallate (EGCG) (BA = -9.4 kcal/mol; RMSD = 0.025 Å) showed strong interactions with the TOP2A protein. To substantiate these findings, the efficacy of hesperetin and EGCG was tested in LC cells. The combination treatment had an IC₅₀ of 78 µg/mL in A549 LC cells and significantly reduced cell proliferation, migration, and TOP2A gene expression, as assessed by MTT assay, wound healing assay, and RT-PCR. The results corroborate the computational predictions and support the utility of EGCG and hesperetin in targeting LC at the cellular level.
Indexed as
Identifiers
41074927What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.